Lupin News and Updates

Keep track of all breaking news on Lupin from all sources in a single place.

Load latest

Lupin Ltd.

07 Nov 2025

2081.80

1.28%

Lupin Shares Climb 2% Led By Strong Q2 Revenue, Operating Income

NDTV Profit

Lupin Q2: The company intends to leverage H1 performance for strong end to fiscal 2026.

Number of FII/FPI investors decreased from 987 to 970 in Sep 2025 qtr

Lupin Q2 PAT rises 73% on strong growth across key global markets

Business Standard | 06 Nov 2025

Lupin Ltd.

30 Oct 2025

2081.80

1.28%

Lupin Digital Health unveils VitaLyfe, AI-driven heart wellness app

Business Standard

The AI-powered platform aims to help working professionals manage cardiometabolic risks through heart-age tracking, personalised nutrition, and guided exercise

Number of FII/FPI investors decreased from 987 to 970 in Sep 2025 qtr

Lupin Ltd.

27 Oct 2025

2081.80

1.28%

India advances anti-dumping probe into TB drug imports from China, Thailand

Business Standard

The DGTR, in a statement on Monday, named Lupin as the domestic industry participant and Chinese producer Wuhan Wuyao Pharmaceuticals Co. Ltd among the foreign respondents

Lupin Ltd. has an average target of 2328.00 from 10 brokers.

Lupin Ltd.

09 Oct 2025

2081.80

1.28%

Lupin shares jump 4% on new Florida manufacturing facility plan

Business Standard

Lupin said the project aims to boost medicine security, diversify supply chains, and reinforce its position as a global leader in respiratory therapies

Number of FII/FPI investors decreased from 987 to 970 in Sep 2025 qtr

Lupin Share Price Rise After Plans To Invest $250 Million In Florida Facility

NDTV Profit | 09 Oct 2025 1 more

Lupin Ltd.

04 Oct 2025

2081.80

1.28%

USFDA issues Form-483 with 4 observations to Lupin's Pithampur Unit-2 facility

Business Line

USFDA inspected the facility from July 8 to 17, 2025, and closed with the issuance of a Form-483 with four observations, the Mumbai-based drug maker said in a regulatory filing

Lupin Ltd. has an average target of 2328.00 from 10 brokers.

Lupin Ltd.

29 Sep 2025

2081.80

1.28%

Lupin Acquires VISUfarma To Expand European Ophthalmology Market Presence

NDTV Profit

VISUfarma B.V. is headquartered in Amsterdam and it is a specialty pharmaceutical company focused on ophthalmology.

Lupin Ltd. has an average target of 2328.00 from 10 brokers.

Lupin subsidiary Nanomi BV inks pact to acquire Netherlands-based VISUfarma

Business Standard | 29 Sep 2025 1 more

Lupin Ltd.

24 Sep 2025

2081.80

1.28%

Lupin gets tentative nod from USFDA for generic HIV treatment drug

Business Standard

Pharma major Lupin Ltd on Wednesday said it has received tentative approval from the US health regulator for its generic version of Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets used to treat human immunodeficiency virus (HIV) infection. The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets of strength 50 mg/200 mg/25 mg, Lupin said in a regulatory filing. This product would be manufactured at Lupin's Nagpur facility, it added. Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets, 50 mg/200 mg/25 mg are bioequivalent to Biktarvy Tablets, 50 mg/200 mg/25 mg of Gilead Sciences, Inc., and indicated for the treatment of human immunodeficiency virus infection in adults and pediatric patients weighing at least 25 kg, it added. Citing IQVIA MAT July 2025 data, Lupin said the Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets (Biktarvy) had

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

20 Sep 2025

2081.80

1.28%

Lupin's Pune Facility Gets Four Observations After US FDA Inspection

NDTV Profit

The US FDA conducted a product-specific pre-approval inspection at the company's Pune biotech facility from Sept. 8 to Sept. 19, according to an exchange filing.

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

18 Sep 2025

2081.80

1.28%

Lupin Gets US FDA Approval For Generic Lenalidomide Capsules

NDTV Profit

Lenalidomide Capsules are indicated for the treatment of adult patients with Multiple myeloma, in combination with dexamethasone.

Geojit BNP Paribas upgraded Lupin Ltd. to Buy with a price target of 2225.0 on 25 Nov, 2025.

Lupin gets USFDA nod for generic cancer drug Lenalidomide capsules

Business Standard | 18 Sep 2025 1 more

Lupin Ltd.

15 Sep 2025

2081.80

1.28%

Lupin, Astra Microwave among top analyst bets; check target, stop-loss

Business Standard

Stocks to buy: Astra Microwave Products has shown a strong movement in the last trading session, while Lupin has recently undergone a notable resurgence

Number of FII/FPI investors decreased from 987 to 970 in Sep 2025 qtr

Is Lupin Ltd. worth buying?

932 Votes:

Buy 72.75%

Sell 17.6%

Hold 9.66%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf